PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Metildigoxin→

Metildigoxin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
30685-43-9
Molecular formula
C42H66O14
Molecular weight
795 g/mol
Drug class
Cardiac glycosidecardiotonic and antiarrhythmic agent
Mechanism of action
Inhibits myocardial Na+/K+-ATPase, increasing intracellular sodium and indirectly increasing intracellular calcium through reduced sodium-calcium exchange. This increases myocardial contractility and also enhances vagal tone, slowing atrioventricular conduction. Metildigoxin is demethylated to digoxin.
Indications / reported uses
  • Historical and jurisdiction-specific use for symptomatic treatment of selected cases of chronic heart failure and supraventricular arrhythmias, including atrial fibrillation; product availability and current use vary by country.

Sources: https://www.ncbi.nlm.nih.gov/mesh/68008520 · https://meshb.nlm.nih.gov/record/ui?dcmsLinks=true&ui=D008520 · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Metildigoxin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Metildigoxin Permitted Daily Exposure (PDE) report (the Metildigoxin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Metildigoxin Occupational Exposure Limit (OEL) report (the Metildigoxin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.